c-Myc

Myc

c-Myc

Related Products

The transcription factor c-Myc is a member of the basic helix-loop-helix leucinezipper (bHLHZip) protein family. The target genes of the c-MYC protein participate in different cellular functions, including cell cycle, survival, protein synthesis, cell adhesion, and micro-RNA expression. c-Myc is also one of the four factors used in reprogramming somatic cells to induce pluripotent stem (iPS) cells and is implicated in maintaining cancer stem-like cells (CSCs). Most biological functions of c-Myc require heterodimerization with its activation partner Max.

c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptional coregulators and histone-modifying enzymes. Deregulated expression of c-MYC caused by gene amplification, retroviral insertion, or chromosomal translocation is associated with tumorigenesis. c-Myc has been identified as a highly promising target for cancer therapy.

c-Myc Related Products (114)
Antibodies (12)

By Effects:	Inhibitors (94) Ligand (1) Degraders (8) Inducers (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-121418

Lusianthridin	Inhibitor	≥98.0%
Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling.

HY-162686

MYC-IN-3	Inhibitor	98.66%
MYC-IN-3 (compound 37) is a potent MYC inhibitor. MYC-IN-3 shows antiproliferative activity. MYC-IN-3 shows anticancer activity. MYC-IN-3 has the potential for the research of prostate cancer.

HY-126979

Mycro2	Inhibitor	99.81%
Mycro2 is an inhibitor of c-Myc/Max dimer and DNA binding, with an IC₅₀ value of 23 μM for the inhibition of Myc/Max DNA binding activity. Mycro2 can inhibit c-myc-dependent cell proliferation, gene transcription and oncogenic transformation.

HY-147651

β-catenin-IN-4	Inhibitor	99.84%
β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a K_i of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc.

HY-147291

VPC-70063	Inhibitor	99.92%
VPC-70063 is a potent Myc-Max inhibitor with an IC₅₀ value of 8.9 μM for Myc-Max transcriptional activity inhibition. VPC-70063 reduces UBE2C promotor activity and AR-V7 levels, and induces PARP cleavage. VPC-70063 induces apoptosis and blocks Myc-Max interactions with DNA. VPC-70063 can be used for researching anticancer.

HY-111522

RK-9123016	Inhibitor	99.02%
RK-9123016 is a potent inhibitor of SIRT2. RK-9123016 inhibits the enzymatic activity of SIRT2 with an IC₅₀ value of 0.18 µM but not other human sirtuin members including SIRT1 and SIRT3 at 100 µM. RK-9123016 increases the acetylation level of eukaryotic translation initiation factor 5A (eIF5A), a physiological substrate of SIRT2, and reduces cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression.

HY-162796

TS-2
TS-2 is a fluorescent ligand of c-Myc G4 with anticancer activity. TS-2 inhibits the growth of cancer cells and induces apoptosis of cancer cells by targeting the c-MYC oncogene promoter G4, causing transcriptional repression of the c-Myc oncogene.

HY-147973

IZTZ-1	Inhibitor
IZTZ-1, an imidazole-benzothiazole conjugate, is a c-MYC G4 ligand. IZTZ-1 is able to downregulate the c-MYC expression by stabilizing c-MYC G4. IZTZ-1 induces cell cycle arrest, apoptosis, thereby inhibiting cell proliferation in B16 cells. IZTZ-1 shows antitumor activity, and can be used for melanoma research.

HY-126771

Chrysomycin A	Inhibitor	≥98.0%
Chrysomycin A (Chr-A), an antibiotic, can be obtained from Streptomyces. Chrysomycin A exhibits antitumor and anti-tuberculous and MRSA activities. As for glioblastoma, Chrysomycin A inhibits the proliferation, migration, and invasion of cancer cells through the Akt/GSK-3β/β-catenin signaling pathway.

HY-124129

10074-A4	Inhibitor	98.22%
10074-A4 is a c-Myc inhibitor. 10074-A4 could bind to c-Myc_370-409 at different sites along the peptide chain. 10074-A4 has anticancer effects.

HY-145748

SYUIQ-5	Inhibitor
SYUIQ-5 is a G-quadruplex ligand. SYUIQ-5 stabilizes G-quadruplex and induce senescence. SYUIQ-5 inhibits c-myc gene promoter activity. SYUIQ-5 induces cancer cells autophagy by triggering telomere damage through TRF2 delocalization from telomeres.

HY-17381A

Idarubicin	Inhibitor
Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts.

HY-111537

rel-AZ5576	Inhibitor
rel-AZ5576 is a selective CDK9 inhibitor with the activity of downregulating Mcl-1 and MYC mRNA transcription and protein expression in diffuse large B-cell lymphoma by inhibiting CDK9, promoting MYC protein turnover, reducing MYC phosphorylation on the stable Ser62 residue and downregulating MYC transcriptional targets, inhibiting the growth of diffuse large B-cell lymphoma cell lines in vitro and in vivo and independent of the cell origin.

HY-171334A

P1D-34	Inhibitor
P1D-34 is a Pin1 PROTAC degrader with a DC₅₀ value of 177 nM. P1D-34 also down-regulates Pin1 client proteins such as Cyclin D1, Rb, Mcl-1, Akt, and c-Myc. P1D-34 shows anti-proliferative activities in a panel of acute myeloid leukemia (AML) cell lines. P1D-34 induces cell DNA damage and apoptosis by releasing ROS generation. Pink: PIN1 ligand (HY-171442A), Blue: CRBN ligand (HY-14658), Black: Linker (HY-W014883).

HY-146660

BRD4 Inhibitor-18	Inhibitor
BRD4 Inhibitor-18 is a highly potent BRD4 inhibitor with an IC₅₀ value of 110 nM. BRD4 Inhibitor-18 has a hydrophobic acetylcyclopentanyl side chain. BRD4 Inhibitor-18 can significantly suppress the proliferation of MV-4-11 cells with high BRD4 level. BRD4 Inhibitor-18 has apoptosis-promoting and G0/G1 cycle-arresting activity.

HY-125978

JY-3-094	Inhibitor
JY-3-094 is a Myc inhibitor that inhibits Myc-Max heterodimer formation (IC₅₀: 33 μM).

HY-173212

PLK1-IN-13	Degrader
PLK1-IN-13 is a selective and orally active PLK1 inhibitor (IC₅₀: 0.27 nM). PLK1-IN-13 also inhibits PLK2 (IC₅₀: 12.72 nM) and PLK3 (IC₅₀: 4.12 nM). PLK1-IN-13 arrests cell at G2 phase, induces apoptosis and down-regulates the transcription of the proliferation-related oncogene c-MYC. PLK1-IN-13 inhibits tumor growth, and can be used for research of acute myeloid leukemia (AML).

HY-168886

Anticancer agent 263	Ligand
Anticancer agent 263 (compound 7) is a potent anticancer agent. Anticancer agent 263 binds to the G-quadruplex DNA (G4) sequence 22-mer Pu22, a mimic of c-Myc DNA. Anticancer agent 263 is a structure modulator, showcasing a significant enhancement in protein α-helix formation and the capability to form supramolecular network. Anticancer agent 263 shows no cytotoxicity.

HY-138071

8α-Tigloyloxyhirsutinolide 13-O-acetate	Inhibitor
8α-Tigloyloxyhirsutinolide 13-O-acetate (8αTGH) is a potent and orally active STAT3 inhibitor. 8α-Tigloyloxyhirsutinolide 13-O-acetate induces early oxidative stress and pyroptosis, and late DNA damage, cell cycle arrest, apoptosis in the TNBC cells. 8α-Tigloyloxyhirsutinolide 13-O-acetate suppresses tumor cell growth in vitro and tumor growth in vivo.

HY-168685

c-Myc ligand 1	Inhibitor
c-Myc ligand 1, a c-Myc inhibitor, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). c-Myc ligand 1 can be used for synthesis PROTAC c-Myc inhibitor 7 (HY-148837).

Name
Email *

	Sorry, but the email address you supplied was invalid.

c-Myc

c-Myc

c-Myc Related Products (114)

Antibodies (12)

c-Myc Related Products (114):